1. "Elsevier Science, Inc."
  2. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (132)
  2. Meeting Abstract (95)
  3. Review (10)
  4. Editorial (2)
  5. Guidelines (2)
  6. Book Section (1)
  7. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (243)
  2. Department of Medicine (203)
  3. Hematologic Malignancies, Division of (197)
  4. GSK Faculty (89)
  5. Adult Leukemia (63)
  6. Sloan Kettering Institute Faculty (62)

More Groups

People
  1. Michel Sadelain (16)
  2. Steven Horwitz (15)
  3. Maria Arcila (12)
  4. Richard O'Reilly (12)
  5. Anas Younes (11)
  6. Hugo Castro-Malaspina (11)

More People

Years
  1. 2024 (4)
  2. 2023 (15)
  3. 2022 (11)
  4. 2021 (17)
  5. 2020 (26)
  6. 2019 (14)

More Years

Publications
  1. Experimental Hematology (53)
  2. Lancet Oncology (30)
  3. The Lancet Haematology (28)
  4. Journal of Molecular Diagnostics (22)
  5. Value in Health (20)
  6. Lancet (12)

More Publications

Publishers
  1. Elsevier Science, Inc. (243)

Results (243)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors
    Meeting Abstract

    Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from the informCLL registry: A prospective, multicenter, observational study of US patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Cll/Sll)
    Meeting Abstract

    Sharman, J.; Barrientos, J. C.; Ghosh, N.; Brander, D.; Gutierrez, M.; Wu, L.; Panjabi, S.; Upasani, S.; Jermain, M.; Naganuma, M.; more...
    Value in Health (2022)

    Fulltext@MSK | Save
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Predictors of major hemorrhage after spleen core biopsy in cancer patients
    Journal Article

    Kunin, H.; Wijetunga, N. A.; Erinjeri, J. P.; Noy, A.; Deipolyi, A. R.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Predictors of adequacy and adverse events during spleen biopsy in oncologic patients
    Meeting Abstract

    Kunin, H.; Wijetunga, N.; Erinjeri, J.; Noy, A.; Deipolyi, A.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
    Review

    Nocco, S.; Andriano, T. M.; Bose, A.; Chilov, M.; Godwin, K.; Dranitsaris, G.; Wu, S.; Lacouture, M. E.; Roeker, L. E.; Mato, A. R.; more...
    Critical Reviews in Oncology/Hematology (2022)

    Fulltext@MSK | Save
  • Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
    Review

    Thanarajasingam, G.; Minasian, L. M.; Bhatnagar, V.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Myocardial composition in light-chain cardiac amyloidosis more than 1 year after successful therapy
    Journal Article

    Cuddy, S. A. M.; Jerosch-Herold, M.; Falk, R. H.; Foley Kijewski, M.; Singh, V.; Ruberg, F. L.; Sanchorawala, V.; Landau, H.; Maurer, M. S.; Yee, A. J.; more...
    JACC: Cardiovascular Imaging (2022)

    Fulltext@MSK | Save